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Acute pericarditis is a clinical syndrome characterized by an intense 
inflammatory response involving the pericardium, generally occurring in 
healthy individuals as an isolated entity or as a manifestation of a 
systemic disease (1). Acute pericarditis was reported in 27.7 cases per 
100,000 person-years in an Italian urban area, being responsible for 
0.1% of all hospital admissions and 5% of emergency room admissions 
for chest pain (2). 
Although its pathogenesis is not completely understood (3), it has 
been hypothesized that acute pericarditis represents a stereotypical 
response to an acute injury to the mesothelial cells of the pericardium (4). 
The trigger, an ‘irritant’, such a virus or cellular debris following a viral 
infection, may activate the NACHT, leucine-rich repeat, and pyrin 
domain-containing protein 3 (NLRP3) inflammasome, a macromolecular 
intracellular complex evolved to sense stress or injury and trigger a local 
or systemic inflammatory response through the release of pro-
inflammatory cytokines, such as interleukin (IL)-1β (5,6). The NLRP3 
inflammasome is formed by the oligomerization of: (i) a sensor, namely 
NLRP3, which is a member of the nucleotide-binding oligomerization 
domain-containing protein (NOD)-like receptor (NLR) proteins; (ii) a 
scaffold protein, the apoptosis-associated speck-like protein containing a 
COOH-terminus caspase activation and recruitment domain (ASC); and 
(iii) an effector, caspase-1, whose activation is strictly required for the 
activity of the inflammasome as it cleaves pro-IL-1β to the active IL-1β 
(6). IL-1α is another isoform of the IL-1 family that is released during 
cellular injury, functioning as an alarmin, and triggering the same 
inflammatory signaling than IL-1β (7,8). Given the limited knowledge on 
its pathophysiology, there are limited treatment options for acute 
pericarditis (9), mostly consisting of non-steroidal anti-inflammatory 
drugs (NSAIDs) and colchicine, with the latter recently being recognized 
as an NLRP3 inflammasome inhibitor and very effective both in acute 
and recurrent pericarditis (10). Recent data also suggest beneficial 
effects of IL-1 blockade with anakinra (4,11). However, none of these 
treatments has been approved by the US Food and Drug Administration 
(FDA) for the treatment of pericarditis in humans. The clinical effect of 
these drugs is hypothesized to be an indirect evidence of the involvement 
of the NLRP3 inflammasome signaling in the pathophysiology of 
pericarditis. However, to date no direct demonstration of the presence of 
the NLRP3 inflammasome in the pericardium during an acute episode of 
pericarditis has been provided. The dearth of pathology studies in 
patients and of animal models of acute pericarditis are likely to explain 
the limited understanding of this syndrome and the lack of targeted 
therapies, which are urgently needed to reduce the disease morbidity. 
The current study aimed i) to detect the presence of the NLRP3 
inflammasome in human pericarditis samples, ii) to develop an innovative 
mouse model of acute pericarditis secondary to NRLP3 inflammasome 
activation, and (iii) to evaluate whether an inhibitory strategy against the 
NLRP3 inflammasome itself or cytokines involved in the activity of the 
inflammasome, i.e. IL-1β as well as IL-1α, could be beneficial as a future 
treatment in patients with pericarditis.  
MATERIAL AND METHODS 
Human pericardial samples 
The Pathology Service of the University of Trieste (Italy) provided 
human samples of patients with chronic pericarditis experiencing an 
acute flare and showing a constrictive evolution who needed 
pericardiectomy (n=6, cases) and pericardial samples from autopsies of 
patients who died for causes not related to pericardial syndromes (n=5, 
controls). The study was approved by the Ethical Committee of the 
Azienda Sanitaria-Universitaria Integrata Trieste (ASUITS), Trieste, Italy. 
Patients gave their consent before entering the study. 
 
Experimental mouse model of acute pericarditis 
Adult male outbred CD1 (8–12 weeks of age) mice were supplied by 
Envigo (Frederick, MD, USA). The experiments were conducted under 
the Guidelines of Laboratory Animals for Biomedical Research published 
by the National Institutes of Health (No. 85-23, revised 2011). The study 
protocol was approved by the Virginia Commonwealth University 
Institutional Animal Care and Use Committee. 
Prior to surgery, mice were put under general anesthesia using 
intraperitoneal injection of pentobarbital sodium (50-70 mg/kg) and 
shaved on the lateral left side of the thorax. Mice were then orotracheally 
intubated and ventilated using a rodent ventilator (Minivent, Harvard 
Apparatus, Holliston, MA, USA). The heart was accessed with the animal 
lying recumbent in the right lateral decubitus position by making a ventral 
to dorsal incision following the curve of the rib cage approximately in the 
region of the 3rd and 4th rib (Figure 1). Muscle layers were then bluntly 
dissected to expose the interosseous space between the 3rd and 4th rib 
granting access to the thoracic cavity. Finally, 1 mg of zymosan A (Sigma 
Aldrich, St. Louis, MO, USA) dissolved in 50 µl of sterile NaCl 0.9% was 
injected under direct visualization into the pericardial space by carefully 
lifting the pericardial sac with curved-tip forceps, using a 30 G needle, 
until a complete distribution of the solution into the pericardium was 
observed (Figure 1). The muscle layers and skin were then brought 
together and closed with 5.0 sutures. Zymosan A is a cell wall extract 
from the yeast Saccharomyces cerevisiae and a known agonist of the 
toll-like receptor-2 (TLR-2). Zymosan A leads to the activation of the 
NLRP3 inflammasome (12) and was already used in mouse models of 
peritonitis and arthritis (13,14). Zymosan A dose was chosen based on 
previous experiments conducted by our group on a model of peritonitis 
induced by the intraperitoneal injection of zymosan A (1 mg/mouse) (15). 
Sham procedures were performed, where mice underwent the same 
surgical procedure injecting an equal volume of sterile NaCl 0.9% in the 
pericardial space (n=4-6). 
 
Treatment of mice following induction of acute pericarditis 
Following the recovery after surgery, mice (6-8 per group) were 
randomly allocated to one of 6 different treatments performed by 
intraperitoneal injection (i.p.) over a period of 1 week: 1) ibuprofen (100 
mg/kg/day, Sigma-Aldrich, St. Louis, MO, USA); 2) colchicine (100 
µg/kg/day, Enzo Life Sciences, Farmingdale, NY, USA); 3) an NLRP3 
inflammasome inhibitor (NLRP3inh) (16673-34-0, 100 mg/kg/day) (16-
18); 4) anakinra, recombinant human IL-1 receptor antagonist (100 
mg/kg/bid, Swedish Orphan Biovitrum, Stockholm, Sweden); 5) 
recombinant murine IL-1 trap, (1, 5 and 30 mg/kg/day every 48h, 
Regeneron Pharmaceuticals, Tarrytown, NY, USA), a fusion protein 
mouse homologue of rilonacept, which combines the ectodomains of the 
IL-1 type 1 receptor (IL-1R1) and IL-1 receptor accessory protein (IL-
1RAcP) to bind and block IL-1α and IL-1β, as previously tested by our 
group (19); 6) matching volume of vehicle (NaCl 0.9%). All drugs were 
administered after surgery and then once daily with the exception of 
anakinra, given twice daily, and IL-1 trap, given once every 48 hours. 
All tested doses of anakinra, NLRP3inh and ibuprofen were 
determined after a thorough review of the previous literature and 
validated in our laboratory (16,17,20-22). IL-1 trap was administered at 3 
different doses (1, 5 and 30 mg/kg) also previously validated in our 
laboratory (19). A dose-response evaluation of colchicine was tested in 
three different concentrations: 100, 500 and 1,000 µg/kg, with the 500 
and 1,000 µg/kg doses resulting in toxicity showing a 100% mortality rate. 
 
Echocardiography 
Transthoracic echocardiography was performed prior to sacrifice at 
day 7 under general anesthesia with pentobarbital (50-70 mg/kg) using 
the Vevo770 imaging system (VisualSonics Inc., Toronto, Ontario, 
Canada) equipped with a 30-MHz probe. Left ventricle was visualized in 
the parasternal short axis view at the mid-ventricular level in the 2D-mode 
echocardiography. The image was optimized for the anterior wall and 
was zoomed to visualize the anterior pericardial structures. After 
optimization of the image, a B-mode and M-mode echocardiogram was 
acquired for optimal spatial-temporal resolution and for measurements of 
the pericardial effusion, defined as the echo-free space between the two 
layers of the pericardium. We, however, considered images acquired 
through B-mode as they were found to be clearer in all subsets of 
animals. 
Two investigators blinded to group allocation measured maximal 
pericardial effusion, expressed as the average among three different 
assessments. 
 
Assessment of pericardial thickness 
Hearts were collected and fixed in 10% formalin for 48 hours, 
dehydrated and embedded in paraffin. Five-μm thick transverse sections 
were deparaffinized, re-hydrated and stained with standard hematoxylin 
and eosin protocol (Sigma Aldrich, St. Louis, MO, USA). Two 
investigators blinded to group allocation measured the thickness of the 
visceral pericardial layers with the aid of a computer morphometry 
analysis software (Image Pro Plus 6.0, Media Cybernetics, Silver Spring, 
MD, USA). 
 
Detection of the NLRP3 inflammasome components in pericardial 
specimens 
Immunofluorescence staining 
ASC represents the scaffold of the NLRP3 inflammasome. Increased 
staining for ASC together with the formation of dense areas of 
aggregation provide evidence for the oligomerization of the 
inflammasome macromolecular structure (23,24). 
In human pericardial samples, ASC expression was evaluated on 3-
μm transverse- sectioned hearts using an immunofluorescence 
technique, as previously described (25,26). Antigen epitopes were 
retrieved with 5 mM citrate buffer pH 6.0 at 95 °C. Slides were incubated 
overnight at 4°C with a primary antibody against human ASC (1:250; 
Sigma Aldrich, St. Louis, MO, USA). Anti-rabbit Alexa Fluor 594-
conjugated (1:100; Invitrogen, Carlsbad, CA, USA) was used as a 
secondary antibody for 4 hours at room temperature. 
Nuclei were counterstained with 4′,6-diamidino-2-phenylindole 
(DAPI) (1:100) for 5 min. Finally, slides were covered after adding 
SlowFade Antifade (Invitrogen, Carlsbad, CA, USA). The images (400× 
magnification) were acquired through Olympus IX70 microscope and 
analyzed by cellSens software (Olympus Life Science, Waltham, MA, 
USA). 
For murine samples, ASC, IL-1α, and IL-1β expression were 
evaluated on 5-μm transversal sections using a primary antibody against 
murine ASC (1:100; Sigma Aldrich, St. Louis, MO, USA), IL-α (1:100; 
R&D Systems, Minneapolis, MN, USA), and IL1-β (1:25; Sigma Aldrich, 
St. Louis, MO, USA), respectively. Anti-rabbit Alexa Fluor 594-
conjugated (1:100; Invitrogen, Carlsbad, CA, USA) was used as a 
secondary antibody for 4 hours at room temperature. Additionally, heart 
slides were incubated with a primary antibody against cardiac α-actin 
(1:200; Sigma-Aldrich, St. Louis, MO, USA) revealed by a secondary 
antibody anti-mouse Alexa Fluor 488-conjugated (1:100; Invitrogen, 
Carlsbad, CA, USA) to identify the myocardial cell and easily identify the 
pericardium, not positive for the cardiac α-actin. 
Quantifications were accomplished for all samples after consensus 
by two different investigators blinded to treatment allocation using a semi-
quantitative scale ranging from 0 to 3 adapted from Abbate et al. (27) 
(Table 1). 
 
Immunohistochemistry staining  
Staining for NLRP3 and cleaved caspase-1 was performed using 
immunohistochemistry. After antigen retrieval, endogenous peroxidases 
were inactivated by a solution of 3% hydrogen peroxide for 15 min. A 
primary antibody raised against mature, active caspase-1 (cleaved 
Asp210, 1:50; ThermoFisher Scientific, Waltham, MA, USA) and NLRP3 
(1:100; Novus Biologicals, Centennial, CO, USA) were incubated 
overnight at 4 °C. An anti-rabbit IgG conjugated to the horseradish 
peroxidase (HRP) secondary antibody was incubated for 2 hours at room 
temperature, followed by incubation with VECTOR® NovaRED™ 
Peroxidase Substrate (1:100; Vector Laboratories, Burlingame, CA, 
USA) and counterstaining with hematoxylin. Finally, slides were 
dehydrated and coverslipped with Cytoseal XYL (ThermoFisher, 
Waltham, MA, USA). Images were acquired using a Zeiss Axio Imager 
A.1 microscope  (Zeiss, Oberkochen, Germany) using 10× objective for 
immunohistochemistry. Quantification was performed as previously 
mentioned (Table 1). 
 
Real-time polymerase chain reaction 
RNA was extracted from the parietal pericardium through affinity 
columns (ReliaPrep™ RNA Miniprep Systems, Promega corporation, 
Madison, WI, USA) and converted to complementary DNA (cDNA) using 
the iScript™ cDNA Synthesis Kit (Biorad, Hercules, CA, USA). Real-time 
polymerase chain reaction (PCR) was done using SsoAdvanced 
Universal SYBR Green Supermix (Biorad, Hercules, CA, USA), with a 
CFX384 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, 
CA, USA). Gene expression was carried for the following mRNAs: Il-1α, 
Il-1β, and Nlrp3. Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) 
was used as a reference gene. 
 
Statistical analysis 
All data are expressed as mean and standard error of the mean 
(SEM). Analysis of variance (ANOVA) was used to analyze differences 
across treatment groups, followed by Student’s t-test for multiple pairwise 
comparisons. Discrete variables between groups were evaluated using 
the Chi square (χ2) test. Pearson's correlation coefficients were 
calculated to evaluate the correlation between pericardial effusion and 
pericardial thickness. A two-sided p-value <0.050 was considered 
statistically significant. All statistical analyses were performed using IBM 
SPSS Statistics for Windows, version 25.0 (IBM CO., Armonk, NY) and 
GraphPad Prism, version 8.2 for Windows (GraphPad Software, La Jolla, 
CA, USA, www.graphpad.com).  
RESULTS 
The NLRP3 inflammasome in human pericarditis 
The expression of the NLRP3 inflammasome components was 
detected in all pericardial samples of patients with chronic pericarditis 
experiencing an acute flare. In particular, NLRP3 and caspase-1 
expression was found upregulated in the human pericardial samples 
(Figure 2A-B), with a significant increased expression compared with 
control subjects (NLRP3: 1.9±0.15 vs. 1.21±0.1, p=0.009 and caspase-
1: 2.5±0.2 vs 1.4±0.09, p<0.001, respectively). As read-out of 
inflammasome activation, ASC aggregates were measured by 
immunofluorescence staining. ASC was found significantly increased in 
pericarditis cases vs. controls (Figure 2C): 2.4±0.2 vs. 1.1±0.3 
(p=0.006). Hence, patients with chronic pericarditis presented an 
intensification of the NLRP3 inflammasome formation and activation 
compared to controls. 
 
Induction of acute pericarditis by zymosan A in the mouse 
Based on literature, zymosan A was shown to induce NLRP3 
inflammasome activation (12-15), and here we used it to develop a 
mouse model of acute pericarditis. In order to assess induction of 
pericarditis, we evaluated three parameters reflecting inflammation of the 
pericardium: presence of pericardial effusion, pericardial thickness, and 
ASC expression. Seven days after the intrapericardial injection of 
zymosan A, mice developed a significantly larger pericardial effusion 
(+83%) compared to sham (p<0.001) (Figure 3A and Figure 4C-D). This 
finding was found already after 3 days from surgery, with zymosan A-
treated mice showing a larger effusion compared with sham mice 
(p<0.001 in B-mode and p=0.004 in M-mode; Figure 4A-B). A 
morphometrical analysis on hematoxylin and eosin stained heart sections 
was carried out at day 7 and revealed a significant increase (45%) in the 
visceral pericardial thickness compared to sham-operated mice 
(p=0.016; Figure 3B). No fibrinous deposits were observed at a 
macroscopic or microscopic evaluation at the time of harvesting. Positive 
correlations between pericardial effusion (assessed through 
echocardiography) and pericardial thickness (assessed through 
histology) were found (Figure 5). At day 7, mice treated with zymosan A 
showed a 60-fold increase expression of ASC compared to sham mice 
indicating activation of the NLRP3 inflammasome (p<0.001; Figure 3C). 
Recent findings highlighted the possible role of both IL-α and IL1-β in 
driving the clinical symptoms (11,28). For this reason, we investigated 
the presence of these two cytokines in our animal model of acute 
pericarditis. A subset of mice, including a group were injected with 
zymosan A and one group with sham mice, were sacrificed 3 days after 
surgery to perform molecular biological analysis and 
immunofluorescence for IL-α and IL1-β. A greater expression of IL-α and 
IL1-β was found both at a transcriptional (Figure 6A) and translational 
level (Figure 6B-C) in mice treated with zymosan A compared with sham-
operated mice. 
Cardiac function was preserved in mice injected with zymosan A and 
in sham mice both at 3 and 7 days. 
In sum, the mouse model of acute pericarditis replicates several 
common features mediated by the local inflammation of the pericardium 
as observed in patients with pericarditis. 
 
Effects of ibuprofen in experimental pericarditis 
Ibuprofen, a cyclooxygenase-2 (COX-2) inhibitor, is currently used as 
a first-line therapy along with colchicine in patients with acute pericarditis 
(1). Treatment with ibuprofen in mice with acute pericarditis reduced 
pericardial effusion compared to vehicle-treated mice by 42% (p<0.001) 
(Figure 7A). In contrast, ibuprofen failed to prevent pericardial thickening 
(Figure 7B) and ASC expression (Figure 7C). 
 
Effects of NLRP3 inflammasome inhibition in experimental pericarditis 
In order to block the NLRP3 inflammasome activity, we used 
colchicine, recently recognized as an NLRP3 inhibitor and largely used 
both in acute and recurrent pericarditis (10) as well as the NLRP3inh 
(16673-34-0), generated here at Virginia Commonwealth University (16) 
and previously tested by our group in experimental myocardial ischemia 
(17,18). Colchicine and the NLRP3inh 16673-34-0 significantly reduced 
pericardial effusion at day 7 by 28% and 46%, respectively (p<0.010 for 
both; Figure 8A). Colchicine was ineffective in reducing pericardial 
thickness, whereas the NLRP3inh 16673-34-0 significantly reduced the 
pericardial thickening by 32% (p=0.003; Figure 8B). ASC aggregation 
was reduced at day 7 both by colchicine (-93% vs. vehicle-treated mice, 
p<0.001) and the NLRP3inh (-78% vs. vehicle-treated mice, p<0.001; 
Figure 8C). 
 
Effects of IL-1 blockade in experimental pericarditis 
IL-1 blockade was evaluated using two different drugs: anakinra, an 
IL-1 receptor antagonist, proposed as treatment for recurrent pericarditis, 
and IL-1 trap, a cytokine trap that prevents soluble IL-1α and IL-1β from 
binding to their receptor, IL-1R1. Treatment with anakinra twice daily 
attenuated pericardial effusion by 13% compared to the vehicle group 
(p<0.050; Figure 9A). Similarly, IL-1 trap given every 48h reduced 
pericardial effusion by 43%, 35% and 33% at all 3 doses tested, 
respectively, compared with the vehicle-treated group (p<0.010 for all 
comparison; Figure 9D). Anakinra reduced pericardial thickening by 20% 
(p<0.050 vs. vehicle; Figure 9B). Similarly, the IL-1 trap consistently 
reduced pericardial thickening (-36%, -42%, and -44%, respectively, 
p<0.001 for all; Figure 9E). Finally, the formation of the inflammasome, 
measured as ASC aggregates, was significantly reduced by anakinra (-
75% vs. vehicle, p<0.001; Figure 9C) and by all of the three doses of IL-
1 trap (-85% for 1 mg/kg, -69% for 5mg/kg and -96% for 30mg/kg, 
p<0.001 for all; Figure 9F). 
Table 2 summarizes main findings of the different tested drugs with 
regard to the efficacy in reducing the pericardial effusion, pericardial 
thickness, and ASC expression.  
DISCUSSION 
In the present study we were able to describe for the first time the 
presence of NLRP3 inflammasome expression in human pericardial 
specimens from patients with pericarditis. We also demonstrated that the 
phenotype of acute pericarditis – thickening of the pericardium, presence 
of an effusion, and inflammation associated with NLRP3 expression – 
can be reproduced in a mouse model with the instillation of zymosan A 
within the pericardial space. The expression of IL-1α and IL-1β in the 
pericardium of mice with acute pericarditis was also demonstrated with a 
higher expression compared with sham mice. Finally, different treatments 
for pericarditis have been tested and results are summarized in Table 2. 
Zymosan A is a TLR-2 agonist and can induce NLRP3 inflammasome 
pathway activation (12,15,17,29). Our mouse model showed that the 
NLRP3 inflammasome promotes the inflammatory changes occurring in 
acute pericarditis, i.e. pericardial effusion and pericardial thickening. As 
supportive evidence, drugs known to inhibit the NLRP3 inflammasome 
pathway – i.e. colchicine, NLRP3inh 16673-34-0, anakinra, and IL-1 trap 
– were found to reduce all or most of the above-mentioned inflammatory 
effects. 
Other models of pericarditis were proposed in the past, using irritating 
agents capable to activate the NLRP3 inflammasome, although there 
was no knowledge about it at the time of publication. Pagé et al. used 
hydrated magnesium silicate (talc) dusted on the pericardium of dogs 
(30). Now we know that silicate crystals can induce the NLRP3 
inflammasome activation (24). The intrapericardial injection of heat-killed 
staphylococci and Freund’s adjuvant in sheep, as performed by Leak et 
al., showed the different stages of the pericardial inflammation, allowing 
to evaluate the inflammatory cell infiltration, the production of fibrin, the 
formation of pericardial adhesions until the final resolution with fibrosis 
(31). The bacterial products of the Freund’s adjuvant (containing 
aluminum) are canonical stimuli for the NLPR3 inflammasome activation 
(32), resulting again in an inflammasome-dependent model of acute 
pericarditis. Recently, a mouse model mimicking pericardial inflammation 
was performed with the intrapericardial injection of blood, minocycline, 
picibanil, and talc through a single-shot injection (33). Compared to 
others, our model has obvious advantages. In fact, the use of large 
animals, such as sheep or dogs, can better mimic what happens in 
humans, but also has clear disadvantages, primarily related to the 
complexity and the costs associated with their housing and handling. We 
therefore believe that the reproduction of the pathophysiological 
alterations of acute pericarditis in the mouse may represent an easy and 
widely replicable model of pericarditis. The model of acute pericarditis 
reflecting the modifications of the acute pericardial inflammation may, 
however, not be adequate to evaluate long-term effects of pericardial 
inflammation, as occurs in chronic pericarditis. However, we are 
interested in tackling the acute phase of the disease presenting with 
disabling symptoms, such as chest pain, and therapies should be 
targeted to block the detrimental effects of the acute phase of the disease 
in order to prevent recurrences (3). Moreover, the use of genetically 
modified mice offers the advantage to study new pathways involved in 
the pathophysiology of pericarditis. 
Although generally self-limiting, pericarditis can be refractory to 
standard therapies and/or recur in approximately 30% of cases (34,35). 
In spite of this, its pathophysiology is still poorly understood and current 
therapeutic strategies are limited and not always effective in avoiding 
recurrences. Indeed, no drug is approved by the US FDA for the 
treatment of acute pericarditis. Currently, NSAIDs are commonly used as 
a first-line treatment but, despite being generally effective in controlling 
symptoms, they did not show a change in the disease course and are 
associated with a significant recurrence rate after discontinuation of 
treatment (1). Accordingly, we found that ibuprofen treatment affects 
some of the features of acute pericarditis in a mouse model. Indeed, 
ibuprofen reduced pericardial effusion but did not prevent the formation 
of the inflammasome nor the pericardial thickening. This effect was 
somewhat expected given its downstream effect on COX-2 with respect 
to the NLRP3 inflammasome (4). 
The limited therapeutic armamentarium is in part due to the scarcity 
of animal models replicating the pathophysiological modifications 
occurring in acute pericarditis. With this regard, our mouse model of 
pericarditis with zymosan A mimics the acute injury occurring into the 
pericardium through which the NLRP3 inflammasome can be activated. 
Indeed, the NLRP3 inflammasome activation was only indirectly 
hypothesized until now, but not yet demonstrated. In fact, the positive 
results with anakinra coming from the AIRTRIP (Anakinra—Treatment of 
Recurrent Idiopathic Pericarditis) trial (11) and others (36) strongly 
supported the hypothesis that the NLRP3 inflammasome importantly 
contribute to the clinical symptoms of the pericardial syndrome. In 
addition, we now demonstrated that the NLRP3 inflammasome is 
expressed by pericardial cells and activates during an acute flare of 
pericarditis leading to the release of IL-1α and IL-1β, that explain the 
typical inflammatory symptoms complained by patients. Release of IL-1α 
from dying cells may also trigger an inflammatory response in pericarditis 
(6,8). While IL-1 has been extensively studied in cardiovascular (i.e. 
acute myocardial infarction and heart failure (37-39)) and rheumatic 
diseases (i.e. rheumatoid arthritis, gout, and adult onset Still’s disease 
(40)), very little is known about its role in pericarditis (3). In this 
manuscript, we reported for the first time the presence and activation of 
the NLRP3 inflammasome in human samples of chronic pericarditis. This 
finding was corroborated by the concurrent presence of all of the three 
components of the inflammasome at the same time (ASC, NLRP3, and 
caspase-1) (6,23,24). We were also able to demonstrate an increased 
expression of IL-1α and IL-1β in the pericardium of mice treated with 
zymosan A compared with sham mice. This suggests that both these 
cytokines are strongly involved in the pathogenesis of acute pericarditis, 
as suggested by a recent report in which canakinumab failed to improve 
steroid-dependent idiopathic recurrent pericarditis in two children (28). In 
addition, blocking IL-1 using both anakinra and IL-1 trap in mice with 
acute pericarditis was highly effective in decreasing pericardial effusion 
and thickness as well as blunting the NLRP3 inflammatory response. 
Anakinra required a high and frequent dosing, consistent with its 
mechanism of action as a receptor antagonist, whereas the IL-1 trap was 
effective across a wide range of dosing and less frequent administrations, 
functioning as an entrapment for circulating IL-1β and IL-1α. In this 
regard, the design of RHAPSODY, a double-blind, placebo-controlled, 
randomized-withdrawal phase 3 trial (NCT03737110) testing rilonacept 
in patients with multiple episodes of recurrent pericarditis has been 
published (41). 
Colchicine is now considered among first-line treatments for both 
acute and recurrent pericarditis based on different clinical trials showing 
its efficacy (1). The main mechanism of colchicine is not completely 
elucidated. Colchicine relies on the inhibition of microtubule 
polymerization and it prevents neutrophil migration (42). Colchicine has 
been shown to interfere with the formation of the macromolecular 
structure of the NLRP3 inflammasome and preventing the association of 
its components and IL-1β release (10,43,44). In our study, colchicine, at 
the dose tested, significantly reduced the pericardial effusion and ASC 
aggregation in the zymosan A pericarditis model, while it failed to prevent 
the pericardial thickening. However, the effects of higher doses of 
colchicine could not be tested due to the toxicity of the drug. The use of 
the NLRP3inh was effective in preventing inflammasome formation, 
reducing pericardial effusion, and reducing pericardial thickening. This is 
of great interest because although colchicine is effective, a significant 
proportion of patients are refractory or cannot tolerate colchicine and 
require additional immunomodulating drugs. The role of the NLRP3inh is 
consistent with the clinical efficacy of IL-1 blockers in preliminary case 
reports (36,45-51). 
This study is, however, not without limitations. Human samples of 
pericarditis came from patients with long-term, chronic pericarditis 
needing pericardiectomy and this may represent a selection bias. 
Unfortunately, pericardiectomy is neither routinely indicated in acute 
pericarditis nor ethically feasible but reserved only for those cases 
presenting with a constrictive evolution. The available pericardial 
specimens were limited in number and additional samples may be 
needed to further confirm and expand our results. The small surgical 
procedures require specialized skills, a learning curve, and are time-
consuming. The mouse model presents clear challenges in the 
assessment of symptoms and behavioral effects. Additionally, the 
surgery in the mouse demands the use of narcotics for pain control, which 
means that chest pain, a common symptom in acute pericarditis, cannot 
be adequately assessed. Pericarditis is often considered related to a viral 
infection or an immune response to the virus, and therefore this model 
may not recapitulate all the upstream events leading to the inflammatory 
response. This animal model was conceived to explore the 
pathophysiological events occurring in acute pericarditis, and not to 
explore long-term effects as in chronic pericarditis. Chronic 
intrapericardial injection of zymosan A is not feasible as it necessitates 
anesthesia and surgery at every time and should be repeated at least 
every 7 days, thus possibly jeopardizing long-term survival of mice. In 
addition, the persistent stress induced on the pericardium by the needle 
may create local inflammation, that could represent a confounder in the 
analysis of results. As the model was designed with a translational 
perspective in mind, we chose to use pharmacological inhibitors and 
chose not to study genetically modified (i.e. NLRP3, IL-1 or IL-1R knock-
out) mice in this study. A systematic characterization of the cellular 
infiltrate in the pericardium was not performed at this time. A post-hoc 
adjustment, such as Dunnett's test, was not considered for multiple 
pairwise comparisons therefore potentially increasing the risk of an 
inflated type I error. Despite its limitations, this model may represent a 
first step to explore novel pathophysiological mechanisms and 
therapeutics in the future.  
CONCLUSION 
We herein demonstrated for the first time the expression and the 
activation of the NLRP3 inflammasome both in humans and in mice with 
pericarditis. Additionally, the instillation of zymosan A within the murine 
pericardium reproduces, through an NLRP3 inflammasome-dependent 
mechanism, the phenotype of acute pericarditis, which is responsive to 
colchicine, NLRP3inh, anakinra, and IL-1 trap. Using a small rodent 
model brings many advantages, including limited cost, ease of use, and 
the ability to manipulate genetic expression. Through this option, it will be 
possible to plan the development of new therapeutic approaches 
targeting NLRP3-driven pathways for further mechanistic and 
translational studies. The study also shows powerful inhibition of the 
inflammatory response in this pericarditis model with inhibitors of IL-1.  
TABLES AND FIGURES 
 





0 No expression No visible aggregates  
1 Low expression 
Few aggregates (<1/high power filed) or mild diffuse 
stain without aggregates 
2 Moderate expression 
1-5 aggregates/high power field or diffuse stain with 
few aggregates 
3 High expression 
Diffuse intense staining with many cytoplasmic 
aggregates (>5/high power field) 
Table 2. Main effects of different pharmacological strategies in the 
animal model of acute pericarditis. 
 





Ibuprofen ++ = = 
Colchicine + = +++ 
NLRP3 
inhibitor ++ ++ +++ 
Anakinra + + +++ 
IL-1 trap ++ ++ +++ 
 
The efficacy of the different treatments on reducing pericardial effusion, 
pericardial thickness, and ASC expression are showed in comparison 
with vehicle (mice injected with zymosan A only). 
Data for IL-1 trap are provided as an average of the three tested doses. 
 
=: no change 
+: reduction between 0 and 30% 
++: reduction between 31% and 60% 





Figure 1. Schematic representation of the experimental mouse 
model of acute pericarditis. Under general anesthesia, 1 mg of 
zymosan A (in 50 µl of sterile NaCl 0.9%) was injected in the pericardial 
sac of the mouse on day 0. Sham control procedures were performed 
injecting an equal volume of sterile NaCl 0.9% in the pericardial sac. 
Selected drugs were administered after the surgery was completed until 





Day 0 Day 7
NSAID
• Ibuprofen daily 
IL-1 antagonists
• Anakinra twice daily
• IL-1 trap every 48h
Mouse Model of Acute Pericarditis  
NLRP3 inhibitors
• Colchicine daily





Figure 2. Upregulation of NLRP3 Inflammasome components in 
human pericardial specimens of patients affected by pericarditis. A) 
Immunohistochemistry reveals upregulation of the NLRP3 protein 
following pericarditis in human samples (original magnification 40×). B) 
Caspase-1 upregulation detected by immunohistochemical staining 
(original magnification 40×). C) Immunofluorescence staining of ASC (in 
red) showing aggregates in the pericardium. Counterstaining of the nuclei 





Figure 3. Assessment of pericarditis in mice. A) Pericardial effusion 
was measured at 7 days by transthoracic echocardiography as echo-free 
space between the two layers of the pericardium. Instillation of zymosan 
A produces a significant increase in pericardial fluid compared to sham 
controls injected with saline. B) Pericardial thickening was measured at 
day 7 by histological assessment of H&E stained heart slides. Zymosan 
A increased significantly the thickness of the visceral pericardial layer 
compared to sham (original magnification 40×) C) Immunofluorescence 
staining for ASC (in red) and cardiac α-actin (green) in the pericardium 
of mice with experimental pericarditis. DAPI was used to counterstain the 


































































Figure 4. Echocardiographic assessment of pericardial effusion at 
day 3 and 7. Assessment of pericardial effusion was performed through 
echocardiography using both B-mode and M-mode modalities at 3 and 7 

















































































Figure 5. Correlations between pericardial effusion and pericardial 
thickness at day 7. Correlations between pericardial effusion (assessed 
through echocardiography)  and pericardial thickness (assessed by 
histology) at day 7 before sacrifice are shown for sham- and vehicle-



















































Figure 6. Assessment of IL-1α and IL-1β in mice. A) IL-1α and IL-1β 
mRNA relative expression in the parietal pericardium was measured at 
three days by real-time polymerase chain reaction (PCR). Mice treated 
with intrapericardial instillation of zymosan A showed a significant 
increase in mRNA expression of both IL-1α and IL-1β compared with 
sham controls injected with saline. B) Pericardial expression of IL-1α was 
measured at day 3 by immunofluorescence staining. Zymosan A-treated 
mice had a higher expression of IL-1α compared with sham. IL-1α 
positive cells are stained in red, while DAPI was used to counterstain the 
nuclei (blue). The myocardium appears green by natural 
autofluorescence. Original magnification 40×. C) Immunofluorescence 
staining for IL-1β (in red) in the pericardium of mice with experimental 
pericarditis demonstrated a higher expression of this cytokine in zymosan 
A-treated mice compared with sham controls. IL-1β is stained in red, 
while DAPI was used to counterstain the nuclei (blue). The myocardium 





Figure 7. Effects of ibuprofen treatment in the experimental model 
of pericarditis in mice. A) Pericardial effusion was measured at 7 days 
following daily treatment with ibuprofen (100 mg/kg). Daily injection with 
ibuprofen significantly reduced fluid accumulation. B) Treatment with 
ibuprofen did not reduce pericardial thickness. C) ASC aggregates were 
not reduced by treatment with ibuprofen. *p<0.05, ***p<0.001 vs sham-





Figure 8. Inhibition of the NLRP3 inflammasome in mice with acute 
pericarditis. A) Pericardial effusion measured at 7 days following daily 
treatment with colchicine (100 µg/kg) and NLRP3inhibitor 16673-34-0 
(100 mg/kg). Colchicine and 16673-34-0 significantly reduced pericardial 
effusion in mice with pericarditis. B) Treatment with the NLRP3 inhibitor 
16673-34-0, but not colchicine, showed a significant reduction of the 
pericardial thickness following acute pericarditis in mice compared to the 
vehicle-treated group. C) ASC aggregates in the pericardium of mice with 
acute pericarditis were significantly reduced by colchicine and 16673-34-
0. *p<0.05, ***p<0.001 vs sham-treated mice; ##p<0.01, ###p<0.001 vs 





Figure 9. IL-1 blockade in experimental acute pericarditis. Pericardial 
effusion, thickness, and formation of ASC aggregates were measured 7 
days after bi-daily treatment with anakinra (100 mg/kg) and IL-1 trap. 
Anakinra significantly reduced A) pericardial fluid accumulation B) 
thickening of the pericardium and C) ASC aggregation following acute 
pericarditis in mice. 
A dose response of IL-1 trap was tested in mice subjected to 
experimental pericarditis. Treatment with IL-1 trap every 48h significantly 
reduced D) pericardial effusion E) pericardial thickness and F) 
inflammasome formation with each dose tested. *p<0.05, ***p<0.001 vs 
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